B. Riley Securities Maintains Buy on OptimizeRx, Raises Price Target to $11

Benzinga Newsdesk www.benzinga.com Positive 75.3%

Neg 0% Neu 0% Pos 75.3%

B. Riley Securities analyst Anderson Schock maintains OptimizeRx (NASDAQ:OPRX) with a Buy and raises the price target from $10 to $11.